Lensar Inc Stock Price, News & Analysis

LENSAR, Inc. (Nasdaq: LNSR) reported a 33% revenue increase to $9.3 million for Q1 2022, driven by a 38% rise in procedure volume to 38,901. The CEO expressed optimism about the forthcoming ALLY Adaptive Cataract Treatment System, which has received FDA acceptance for its 510(k) application and is expected to launch this year. However, the net loss widened to $6.7 million from $5.2 million year-over-year. R&D expenses surged 74% due to ALLY's development costs, while cash reserves decreased to $29 million, indicating the need for careful cash management going forward.

LENSAR, Inc. (NASDAQ: LNSR) will announce its first quarter 2022 financial results before market open on May 9, 2022. A conference call and webcast will follow at 8:30 am ET, where management will discuss financial outcomes and corporate highlights. LENSAR specializes in advanced femtosecond laser systems for cataract treatment, integrating proprietary technologies aimed at enhancing surgical efficiency and visual outcomes.

LENSAR reported a 31% increase in 2021 revenue, reaching $34.5 million, driven by a 37% rise in procedure volume in Q4. The company submitted the ALLY™ 510(k) application to the FDA, aiming for a commercial launch later this year. While fourth-quarter revenue hit $11.2 million, the net loss improved to ($3.9 million) from ($6.8 million) year-over-year. Cash and cash equivalents were $31.6 million, a decrease from $40.6 million the previous year. Operating expenses declined due to lower stock-based compensation, despite increased R&D spending.

LENSAR, Inc. (NASDAQ: LNSR) announced FDA acceptance of its 510(k) submission for the ALLY™ Adaptive Cataract Treatment System. This submission marks a key milestone in its two-step commercialization strategy, aimed at enhancing cataract surgery with improved technology. The company plans to file an additional application for phacoemulsification features later in 2022. If cleared, LENSAR expects to launch the ALLY system in the second half of 2022, which may optimize surgical efficiency and patient outcomes, according to CEO Nick Curtis.

LENSAR, Inc. (LNSR), a medical technology company specializing in femtosecond laser systems for cataract treatment, will release its Q4 2021 and full year results on March 3, 2022, before the market opens. A conference call with management will follow at 8:30am ET the same day, accessible via phone or webcast through the company's website. LENSAR is committed to enhancing surgical outcomes with its innovative laser solutions, designed to improve efficiency and precision in cataract surgeries.

LENSAR, Inc. (NASDAQ: LNSR), a medical technology company specializing in femtosecond laser solutions for cataract treatment, will have CEO Nick Curtis participate in two investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 9:30 a.m. ET, and the second is the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 2:20 p.m. ET. The SVB Leerink chat can be accessed via LENSAR's website, and the recording will be available for a month post-event.

LENSAR, Inc. (NASDAQ: LNSR), a leader in medical technology for cataract treatment, has announced that CEO Nick Curtis will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting January 10, 2022, at 7:00 a.m. Eastern Time, accessible through the Investors section of the company's website. LENSAR specializes in advanced femtosecond laser systems aimed at improving surgical outcomes for cataracts and corneal astigmatism, incorporating proprietary technologies for enhanced precision and efficiency.

LENSAR, Inc. (NASDAQ: LNSR) has announced that CEO Nick Curtis will present at two upcoming investor conferences. The first, the Piper Sandler 33rd Annual Virtual Healthcare Conference, will feature an on-demand presentation available starting November 22 at 10:00 a.m. ET. The second event, BTIG Ophthalmology Day, will include a fireside chat on November 30 at 8:00 a.m. ET. The Piper Sandler presentation can be accessed on the Company’s website, where it will be available for one month after being posted.

LENSAR, Inc. (NASDAQ: LNSR) announced two poster presentations accepted for the American Academy of Ophthalmology (AAO) Annual Meeting, scheduled for November 12-15, 2021. The presentations highlight the use of LENSAR's femtosecond laser technology in improving astigmatic outcomes during cataract surgery. The topics are:

• Femtosecond Laser Image Guided Corneal Arcuate Incisions for Managing Mild Keratometric Astigmatism in Cataract Surgery
• Toric IOL alignment with femtosecond laser capsular marks confirmed by intraoperative aberrometry